1,800
Views
6
CrossRef citations to date
0
Altmetric
Research Articles

A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease

ORCID Icon, &
Pages 2327-2338 | Received 15 Jul 2020, Accepted 12 Oct 2020, Published online: 23 Oct 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Chandran S. Abhinand, Athira A. Prabhakaran, Anand Krishnamurthy, Rajesh Raju, Thottethodi Subrahmanya Keshava Prasad, Achuthsankar S. Nair, Kallikat N. Rajasekharan, Oommen V. Oommen & Perumana R. Sudhakaran. (2023) SARS-CoV-2 variants infectivity prediction and therapeutic peptide design using computational approaches. Journal of Biomolecular Structure and Dynamics 41:20, pages 11166-11177.
Read now

Articles from other publishers (4)

Jian-Xin Shen, Wen-Wen Du, Yuan-Ling Xia, Zhi-Bi Zhang, Ze-Fen Yu, Yun-Xin Fu & Shu-Qun Liu. (2023) Identification of and Mechanistic Insights into SARS-CoV-2 Main Protease Non-Covalent Inhibitors: An In-Silico Study. International Journal of Molecular Sciences 24:4, pages 4237.
Crossref
Amani Toumi, Sarra Boudriga, Yasmine M. Mandour, Ahmed A. Mekki, Michael Knorr, Carsten Strohmann, Jan-Lukas Kirchhoff & Mansour Sobeh. (2022) Design of Novel Enantiopure Dispirooxindolopyrrolidine-Piperidones as Promising Candidates toward COVID-19: Asymmetric Synthesis, Crystal Structure and In Silico Studies. Molecules 27:12, pages 3945.
Crossref
Guillem Macip, Pol Garcia‐Segura, Júlia Mestres‐Truyol, Bryan Saldivar‐Espinoza, María José Ojeda‐Montes, Aleix Gimeno, Adrià Cereto‐Massagué, Santiago Garcia‐Vallvé & Gerard Pujadas. (2021) Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition. Medicinal Research Reviews 42:2, pages 744-769.
Crossref
Aslı Deniz Aydın, Faruk Altınel, Hüseyin Erdoğmuş & Çağdaş Devrim Son. (2021) Allergen fragrance molecules: a potential relief for COVID-19. BMC Complementary Medicine and Therapies 21:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.